Results add to a growing body of positive late-stage evidence for Ris-Rez, including recent pivotal data in advanced or relapsed small-cell lung cancer

GSK is advancing development of Ris-Rez outside China across multiple tumour types, including lung cancer, prostate cancer and other solid tumours

https://www.gsk.com/en-gb/media/press-releases/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii-trial-for-ris-rez-in-china/